Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients

Gemcitabine and treosulfan are DNA-damaging agents. Preclinical studies suggest that synergism exists when melanoma cells are exposed to both drugs concurrently. We conducted a phase I trial in advanced melanoma patients to determine the optimal dose of gemcitabine to be combined with treosulfan. Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrie, P G, Shaw, J, Spanswick, V J, Sehmbi, R, Jonson, A, Mayer, A, Bulusu, R, Hartley, J A, Cree, I A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361787/
https://www.ncbi.nlm.nih.gov/pubmed/15886706
http://dx.doi.org/10.1038/sj.bjc.6602586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361787/
https://www.ncbi.nlm.nih.gov/pubmed/15886706
http://dx.doi.org/10.1038/sj.bjc.6602586

Ejemplares similares